Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: CD69

Summary for CD69

Gene information	Gene symbol	CD69
	Ensembl ID	ENSG00000110848
	Entrez ID	969
	Gene name	CD69 molecule
	Synonyms	CLEC2C
	Gene type	protein_coding
	UniProtAcc	Q07108

Top

Dataset with differentially expressed gene: CD69

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.350832	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.335317	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.354971	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	0.296736	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	B cells	0.359244	5.41e-06
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.795773	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	1.00015	6.93e-37
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.528401	0.00e+00
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	-0.397181	4.49e-19
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	0.345001	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	NK cells	0.462857	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	0.537713	9.81e-12
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	0.456444	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	0.396703	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD8+ T cells	-0.348195	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	pre	CD4+ T cells	0.31333	7.65e-24
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-1.26205	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-0.890448	0.00e+00
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	post	B cells	0.447325	8.24e-26
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	pre	CD8+ T cells	0.258619	0.00e+00
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	pre	CD4+ T cells	0.361111	0.00e+00
GSE150930	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Mucosa-assisted lymphoid tissue (MALT) lymphoma	Immunotherapy	rituximab + cyclophosphamide + fludarabine	NA	Malignant cells	-0.4228	3.71e-13
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mast cells	1.35625	2.30e-03
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	0.792895	1.71e-22
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	CD4+ T cells	-0.347139	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	CD4+ T cells	0.374822	7.30e-22
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.59779	3.17e-10
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	1.4305	4.62e-10
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD8+ T cells	-0.289147	1.37e-17
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	NK cells	-0.46017	1.47e-03
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	1.02606	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	NK cells	0.811399	1.68e-15
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD4+ T cells	0.356654	2.97e-07
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	0.960438	1.66e-36
GSE152469	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	NA	CD8+ T cells	0.827841	3.51e-19
GSE152469	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	NA	Malignant cells	1.19103	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	NK cells	-0.525409	1.93e-24
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD8+ T cells	-0.496784	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	CD4+ T cells	-0.583669	2.14e-06
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	B cells	-1.43438	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	NK cells	-1.05609	4.92e-14

Top

Expression of CD69 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to CD69

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating CD69

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
CD69	hsa-miR-32-5p	99.9847	NM_001781
CD69	hsa-miR-92a-3p	99.9847	NM_001781
CD69	hsa-miR-92b-3p	99.9847	NM_001781
CD69	hsa-miR-367-3p	99.9802	NM_001781
CD69	hsa-miR-363-3p	99.9802	NM_001781
CD69	hsa-miR-25-3p	99.9802	NM_001781
CD69	hsa-miR-5589-3p	95.9953	NM_001781
CD69	hsa-miR-454-3p	93.2374	NM_001781
CD69	hsa-miR-95-5p	93.0445	NM_001781
CD69	hsa-miR-130b-3p	92.7212	NM_001781
CD69	hsa-miR-20a-5p	92.6152	NM_001781
CD69	hsa-miR-106b-5p	92.6152	NM_001781
CD69	hsa-miR-450a-2-3p	91.3376	NM_001781
CD69	hsa-miR-93-5p	91.3169	NM_001781
CD69	hsa-miR-106a-5p	91.3169	NM_001781
CD69	hsa-miR-17-5p	91.3169	NM_001781
CD69	hsa-miR-519d-3p	91.3169	NM_001781
CD69	hsa-miR-526b-3p	91.3169	NM_001781
CD69	hsa-miR-20b-5p	91.3169	NM_001781
CD69	hsa-miR-301b-3p	91.2119	NM_001781
CD69	hsa-miR-3666	91.2119	NM_001781
CD69	hsa-miR-130a-3p	91.2119	NM_001781
CD69	hsa-miR-301a-3p	91.2119	NM_001781
CD69	hsa-miR-4295	91.2119	NM_001781
CD69	hsa-miR-4699-5p	87.7887	NM_001781
CD69	hsa-miR-142-5p	87.7458	NM_001781
CD69	hsa-miR-5590-3p	87.7458	NM_001781
CD69	hsa-miR-6774-5p	87.7404	NM_001781
CD69	hsa-miR-635	87.7404	NM_001781
CD69	hsa-miR-431-5p	86.2966	NM_001781
CD69	hsa-miR-181c-3p	85.3076	NM_001781
CD69	hsa-miR-6874-3p	83.6645	NM_001781
CD69	hsa-miR-148b-5p	83.6645	NM_001781
CD69	hsa-miR-2110	83.6323	NM_001781
CD69	hsa-miR-548an	82.9896	NM_001781
CD69	hsa-miR-3646	82.6985	NM_001781
CD69	hsa-miR-4262	82.4076	NM_001781
CD69	hsa-miR-4796-3p	81.5778	NM_001781
CD69	hsa-miR-181d-5p	80.0735	NM_001781
CD69	hsa-miR-181a-5p	80.0735	NM_001781
CD69	hsa-miR-181c-5p	80.0735	NM_001781
CD69	hsa-miR-181b-5p	80.0735	NM_001781

Page: 1

Top

Motifs and transcription factors (TFs) regulating CD69

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
CD69	taipale_cyt_meth__CREB1_NRTGACGTN_eDBD_repr	CREB1 (directAnnotation).
CD69	jaspar__MA0604.1	ATF1 (inferredBy_Orthology).
CD69	transfac_pro__M06251	ZSCAN2 (inferredBy_Orthology).
CD69	metacluster_156.2	ATF3; ATF4; ATF4; ATF4; ATF4; ATF4; ATF4; CEBPG; CEBPG; DDIT3; MYC (directAnnotation). ATF4; ATF4; ATF4; CEBPG; DDIT3 (inferredBy_Orthology).
CD69	taipale_tf_pairs__ATF4_CEBPD_NGATGATGCAATNN_CAP	ATF4; CEBPD (directAnnotation).
CD69	tfdimers__MD00204	GABPA; NKX2-1 (directAnnotation).
CD69	metacluster_8.1	ZNF382 (directAnnotation).
CD69	taipale_tf_pairs__FLI1_FOXI1_RCCGGATGTTKWY_CAP	FLI1; FOXI1 (directAnnotation).
CD69	taipale_tf_pairs__ELK1_TEF_NSCGGAWNTTACGTAAN_CAP	ELK1; TEF (directAnnotation).
CD69	taipale_tf_pairs__ATF4_TEF_RNMTGATGCAATN_CAP	ATF4; TEF (directAnnotation).
CD69	transfac_pro__M03888	SOX6 (directAnnotation).
CD69	dbtfbs__GMEB1_K562_ENCSR928KOR_merged_N1	GMEB1 (directAnnotation).
CD69	transfac_pro__M06917	ZNF236 (directAnnotation).
CD69	tfdimers__MD00084	ARID3A; NKX2-4 (directAnnotation).
CD69	metacluster_111.4	ATF1; ATF1; ATF1; ATF1; ATF1; ATF1; ATF2; ATF2; ATF2; ATF2; ATF2; ATF2; ATF2; ATF2; ATF2; ATF2; ATF3; ATF3; ATF3; ATF3; ATF3; ATF4; ATF4; ATF5; ATF6; ATF6B; ATF7; ATF7; ATF7; BATF3; BATF3; CREB1; CREB1; CREB1; CREB1; CREB1; CREB1; CREB1; CREB1; CREB1; CREB1; CREB3; CREB3L4; CREB3L4; CREB5; CREB5; CREB5; CREM; CREM; CREM; CREM; CREM; FOSB; FOSL1; FOSL1; FOSL2; JDP2; JDP2; JDP2; JUN; JUNB; JUNB; JUNB; JUND; JUND; JUND; JUND; JUND; XBP1; XBP1; XBP1; ZNF629 (directAnnotation). ATF1; ATF1; ATF1; ATF2; ATF2; ATF3; ATF6; ATF6B; ATF7; ATF7; ATF7; ATF7-NPFF; ATF7-NPFF; ATF7-NPFF; ATF7-NPFF; BATF; BATF2; BATF3; CREB1; CREB1; CREB3; CREB3L1; CREB3L2; CREB3L3; CREB3L4; CREM; FOS; FOSB; FOSL1; FOSL2; JDP2; JDP2 (inferredBy_Orthology).
CD69	metacluster_137.2	ATF3; BACH2; BATF; BATF; BATF; BATF; BATF3; FOS; FOS; FOS; FOS; FOS; FOS; FOS; FOS; FOS; FOS; FOSB; FOSB; FOSB; FOSB; FOSB; FOSL1; FOSL1; FOSL1; FOSL1; FOSL1; FOSL2; FOSL2; FOSL2; FOSL2; FOSL2; FOSL2; FOSL2; INSM2; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUNB; JUNB; JUNB; JUNB; JUNB; JUND; JUND; JUND; JUND; JUND; SMARCC1 (directAnnotation). ATF3; ATF3; BATF; FOS; FOSB; FOSL1; FOSL1; FOSL2; FOSL2; FOSL2; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUNB; JUND; JUND; JUND; JUND (inferredBy_Orthology).
CD69	transfac_pro__M02279	CREB1 (directAnnotation).
CD69	tfdimers__MD00376	HOXA13; KLF4 (directAnnotation).
CD69	transfac_public__M00039	CREB1 (directAnnotation).
CD69	transfac_pro__M05794	ZNF621 (directAnnotation).
CD69	metacluster_132.4	MEF2B; MEF2B; MEF2B; MEF2B; MEF2C; MEF2C; MEF2D; MEF2D; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF (directAnnotation). SRF; SRF; SRF; SRF (inferredBy_Orthology).
CD69	taipale_tf_pairs__TEAD4_ERG_RSCGGAAATRCC_CAP	ERG; TEAD4 (directAnnotation).
CD69	taipale__ELK1_full_NACTTCCGSCGGAARMN_repr	ELK1 (directAnnotation).
CD69	metacluster_5.1	HIVEP1; HIVEP1; NFAT5; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB2; NFKB2; NFKB2; NFKB2; NFKB2; REL; REL; REL; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELB; RELB (directAnnotation). NFAT5; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB2; NFKB2; NFKB2; REL; REL; REL; REL; RELA; RELA; RELA; RELA; RELA; RELB; RELB; RELB (inferredBy_Orthology).
CD69	transfac_pro__M05745	ZNF718 (directAnnotation).
CD69	transfac_pro__M05935	ZNF382 (directAnnotation).
CD69	taipale_tf_pairs__ETV5_FOXI1_TGTTGNCGGAWRN_CAP	ETV5; FOXI1 (directAnnotation).
CD69	taipale_tf_pairs__POU2F1_ELK1_NCCGGATATGCAN_CAP	ELK1; POU2F1 (directAnnotation).
CD69	taipale_tf_pairs__HOXB2_ETV1_ACCGGAAATGA_CAP	ETV1; HOXB2 (directAnnotation).
CD69	transfac_pro__M05896	ZNF713 (directAnnotation).
CD69	hocomoco__GMEB2_HUMAN.H11MO.0.D	GMEB2 (directAnnotation).
CD69	transfac_pro__M06248	ZNF91 (directAnnotation).
CD69	taipale_tf_pairs__ELK1_FOXI1_WGTTKMCGGAWRTN_CAP	ELK1; FOXI1 (directAnnotation).
CD69	metacluster_190.8	ILF2; NFAT5; NFAT5; NFAT5; NFAT5; NFATC1; NFATC2; NFATC3; NFATC4; NFATC4 (directAnnotation).
CD69	metacluster_126.1	ZNF549; ZNF549; ZNF549 (directAnnotation).
CD69	metacluster_58.7	FOS; JUN; NFATC1 (directAnnotation).
CD69	metacluster_172.6	CHD2; E2F1 (directAnnotation).
CD69	tfdimers__MD00014	ARID3A; KLF4 (directAnnotation).
CD69	transfac_pro__M05347	NR2C1 (directAnnotation).
CD69	metacluster_88.6	ZNF214 (directAnnotation).
CD69	transfac_pro__M05706	ZNF20 (directAnnotation).
CD69	swissregulon__hs__ZNF691	ZNF691 (directAnnotation).
CD69	transfac_pro__M06721	ZKSCAN7 (directAnnotation).
CD69	transfac_pro__M04870	HDAC2 (directAnnotation).
CD69	transfac_pro__M07268	SOX4 (directAnnotation).
CD69	swissregulon__hs__NANOG	NANOG (directAnnotation).
CD69	homer__ACAGGATGTGGT_ETS_RUNX	RUNX1 (directAnnotation).
CD69	transfac_pro__M06725	ZNF624 (directAnnotation).
CD69	transfac_pro__M07479	ZNF35 (directAnnotation).
CD69	metacluster_50.1	BATF; BATF; BATF; BATF; BNC2; FOS; FOSB; FOSL1; FOSL1; IRF4; JUN; JUN; JUNB; JUNB; JUNB; JUNB; JUND; JUND; JUND; JUND; JUND; SMAD2; SMAD3 (directAnnotation). BATF; BATF; BATF; FOS; FOSL1; FOSL2; JDP2; JUN; JUN; JUND (inferredBy_Orthology).

Page: 1 2 3 4

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."